ImmunityBio, Inc. IBRX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
- ImmunityBio, Inc. (IBRX) reported share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price of $4.98 in Q1 2026.
- How has ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price changed year-over-year?
- ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price decreased by 19.4% year-over-year, from $6.18 to $4.98.
- What is the long-term trend for ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, weighted average exercise price has grown at a -13.0% compound annual growth rate (CAGR), from $9.96 to $4.97.